CERTIFICATE OF ANALYSIS – TECHNICAL DATA SHEET

Product name	FHR-2, Human, mAb 2.12		
Catalog number	HM2433-100UG		
Lot number	-	**Expiry date**	-
Volume	1 ml	**Amount**	100 µg
Formulation	0.2 µm filtered in PBS+0.02%NaN3+0.1%BSA	**Concentration**	100 µg/ml
Host Species	Mouse IgG1	**Conjugate**	None
Endotoxin	N/A	**Purification**	Protein G
Storage	4°C		

Application notes

	IHC-F	IHC-P	IF	FC	FS	IA	IP	W
Reference #								-
Yes								●
No								
N.D.	●	●	●	●	●	●	●	

N.D.= Not Determined; IHC = Immuno histochemistry; F = Frozen sections; P = Paraffin sections; IF = Immuno Fluorescence; FC = Flow Cytometry; FS = Functional Studies; IA = Immuno Assays; IP = Immuno Precipitation; W = Western blot



W: Western blot analysis performed with human FHR-2 protein with antibody 2.12 (HM2433) at 2 µg/ml .

Dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.

- W: A non-reduced sample treatment and SDS-Page was used. The band sizes around ~25-30 kDa.

All Hycult Biotech products are subject to strict quality control procedures.
Copyright® Hycult Biotech. All rights reserved.
The information on this data sheet should neither be considered comprehensive or definitive.

General Information

Description	HM2433 (anti-FHR-2; clone 2.12) is a mouse monoclonal antibody recognizing human full length Complement Factor H-related protein 2 (FHR-2), a glycoprotein belonging to the family of complement regulatory proteins. FHR-2 has a molecular weight of approximately 29 kDa and is synthesized and secreted primarily by the liver but also by various immune cells, including monocytes, macrophages, and dendritic cells. Structurally, FHR-2 shares homology with Complement Factor H (CFH), which is a key regulatory protein within the complement system. Also FHR-2 is involved in the regulation of the complement cascade but its biological role is poorly understood somewhat controversial. Studies showed that FHR-2 inhibits the activity of the complement alternative pathway (AP) C3 convertase, thereby preventing MAC formation. On the other hand, it is described that a hybrid mutant protein consisting of FHR-5 domains and full length FHR-2 causes complement overactivation, which suggests that FHR-2 rather promotes AP activation. Dysregulation of FHR-2 is associated with diseases such as atypical hemolytic uremic syndrome (aHUS) and age-related macular degeneration (AMD). In these diseases, abnormal complement activation and deposition on host tissues can contribute to pathological processes. FHR-2's involvement in the alternative pathway of the complement system positions it as a potential target for therapeutic interventions aimed at modulating complement-related diseases.
Immunogen	Human Complement factor H-related protein 2
Aliases	CFHL2, CFHR2, HFL3
Gene	Gene name: CFHR2 Entrez Gene ID: 3080 Uniprot: P36980
Storage&stability	Product should be stored at 4°C. Under recommended storage conditions, product is stable for at least one year.
Precautions	For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.

We hereby certify that the above-stated information is correct and that this product has been successfully tested by the Quality Control Department. This product was released for sale according to the existing specifications. This document has been produced electronically and is valid without a signature.

Approved by Manager of QC

Date

Do you have any questions or comments regarding this product? Please contact us via support@hycultbiotech.com.

All Hycult Biotech products are subject to strict quality control procedures.
Copyright® Hycult Biotech. All rights reserved.
The information on this data sheet should neither be considered comprehensive or definitive.